A phase II study of amrubicin, a synthetic 9-aminoanthracycline, in patients with previously treated lung cancer.
Abstract | PURPOSE: METHODS: Eligible patients were required to have recurrent or refractory NSCLC and SCLC after one or two previous chemotherapy regimens. All patients received intravenous amrubicin 35 mg/m(2) on days 1-3 every 3 weeks. Overall response rate (ORR), progression-free survival (PFS), and overall survival (OS) were evaluated. RESULTS: Sixty-six patients (37 NSCLC and 29 SCLC) were assessable for efficacy and safety evaluation. Grade 3 or 4 neutropenia was observed in 39.4% of all patients (NSCLC, 37.8%; SCLC, 41.4%). Nonhematological toxicities were mild. No treatment-related death was observed. The ORRs were 13.5% (95% CI, 4.5-28.8%) in NSCLC and 44.8% (95% CI, 26.4-64.3%) in SCLC. In SCLC, ORRs were 60.0% in the sensitive relapse and 36.8% in the refractory relapse (p=0.2332). In NSCLC, the PFS, OS, and 1-year survival were 3.3 months, 12.0 months, and 35.3%, respectively. In SCLC, the PFS, OS, and 1-year survival were 4.0 months, 12.0 months, and 46.7%, respectively. CONCLUSIONS:
Amrubicin is an active and well-tolerated regimen in patients with previously treated lung cancer. Amrubicin 35 mg/m(2) seems to achieve similar efficacy with less toxicity than amrubicin 40 mg/m(2) in this patient population. These results warrant further evaluation in previously treated lung cancer.
|
Authors | Kyoichi Kaira, Noriaki Sunaga, Yoshio Tomizawa, Noriko Yanagitani, Kimihiro Shimizu, Hisao Imai, Mitsuyoshi Utsugi, Yasuki Iwasaki, Hironobu Iijima, Hiroaki Tsurumaki, Akihiro Yoshii, Naoto Fueki, Takeshi Hisada, Tamotsu Ishizuka, Ryusei Saito, Masatomo Mori |
Journal | Lung cancer (Amsterdam, Netherlands)
(Lung Cancer)
Vol. 69
Issue 1
Pg. 99-104
(Jul 2010)
ISSN: 1872-8332 [Electronic] Ireland |
PMID | 19853960
(Publication Type: Clinical Trial, Phase II, Journal Article)
|
Copyright | Copyright 2009 Elsevier Ireland Ltd. All rights reserved. |
Chemical References |
- Anthracyclines
- Antineoplastic Agents
- amrubicin
|
Topics |
- Aged
- Anthracyclines
(administration & dosage, adverse effects)
- Antineoplastic Agents
(administration & dosage, adverse effects)
- Carcinoma, Non-Small-Cell Lung
(drug therapy, pathology)
- Disease-Free Survival
- Female
- Humans
- Lung Neoplasms
(drug therapy, pathology)
- Male
- Middle Aged
- Small Cell Lung Carcinoma
(drug therapy, pathology)
|
|
Join CureHunter, for free Research Interface BASIC access!
Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease.
Find out why thousands of doctors, pharma researchers and patient activists
around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!
|